The synchronized footage, published online in January, was assembled by a mostly anonymous online group of sleuths called Osint HK, which has been keeping tabs on protesters and journalists’ often-violent encounters with police during the more than eight months of Hong Kong’s near-daily anti-government, pro-democracy protests. Osint HK has spent hours each day scouring social networks for videos and other media to document police misconduct across Hong Kong.

The protests are still happening, but they’ve slowed due to fears over the coronavirus, which has been spreading from China across the globe. So Osint HK more recently has begun focusing its efforts on educating the public about the virus.

“People are confused, and they don’t know where to turn,” says Trey Menefee, the founder and public face of Osint HK. “We are trying to be a trusted source of information, cutting through the fog to find out what did or didn’t happen.”

Masoumeh Ebtekar, President Hassan Rouhani’s deputy for women’s affairs and the highest-ranking woman in the government, was at least the seventh Iranian official to test positive.

Regeneron will work with the U.S. government to develop antibody treatments for the new coronavirus from China, disclosing Tuesday an expansion of a partnership that previously yielded an experimental drug cocktail for the Ebola virus.

The Tarrytown, New York-based biotech is one of roughly a dozen drugmakers now working on treatments for the coronavirus that emerged late last year in Wuhan, China. Most are smaller companies unlikely to possess sufficient funds to run large-scale tests, although Johnson & Johnson and Gilead have announced initial efforts in recent weeks.

The biotech hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn’t easy.